A phase II randomized controlled trial of orally administered yeast-derived β-glucan for alleviating chemoradiotherapy-induced oral mucositis in nasopharyngeal carcinoma patients
Oral PGG significantly reduces severe mucositis incidence and mitigates nutritional deterioration during NPC chemoradiotherapy without added toxicity.
Authors
- Renwei Jiang
- Xi Xie (ORCID: https://orcid.org/0000-0001-7406-8444)
- Yuanling Luo
- Zongping Han
- Feixia Zhuo
- Shuai Wang (ORCID: https://orcid.org/0000-0003-3946-4497)
- Feng Li (ORCID: https://orcid.org/0000-0001-5892-6496)
- Li Yu (ORCID: https://orcid.org/0000-0001-6872-2665)
- Xiwei Xu
- Jinman Chen
- Qingfeng Yang
- Fanglin Xie
Institutions
- Sun Yat-sen University (CN)
- Fifth Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-03-09
- DOI
- https://doi.org/10.3389/fonc.2026.1775554
- Primary Topic
- Oral health in cancer treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00